Adaptive Case Series — Adaptive Case Series Study
Adaptive Case Series Study · Also known as: adaptive case-series design, sequential adaptive case series, adaptive observational case series
An adaptive case series is an observational study design that documents a consecutive group of patients with a shared condition or exposure while incorporating pre-specified rules for modifying data collection, monitoring, or stopping criteria as accumulating evidence warrants. It combines the descriptive richness of traditional case series with the prospective flexibility of adaptive design principles, enabling structured mid-course adjustments without compromising the integrity of the recorded clinical observations.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
An adaptive case series is appropriate when you need to describe clinical outcomes in a series of patients while retaining the ability to respond to emerging findings mid-study — for example, during early post-marketing surveillance of a device or drug, or when characterising a rare disease where initial patient numbers are uncertain. It suits situations where the full scope of the study cannot be fixed in advance due to evolving clinical understanding. Do not use it when a controlled comparison group is needed to estimate causal effects; the lack of a comparator means associations with outcomes cannot be attributed to the exposure or intervention. Also avoid it when regulatory or ethical requirements mandate a fully fixed protocol with no mid-study modifications.
Strengths & limitations
- Preserves the descriptive granularity of traditional case series while building in structured responsiveness to emerging data.
- Pre-specified adaptation rules prevent post-hoc, opportunistic changes that would inflate false-positive rates.
- Useful for rare conditions where initial sample size cannot be reliably estimated and iterative enrollment is pragmatic.
- Supports early safety signal detection through planned interim monitoring without requiring a comparator group.
- Can be deployed rapidly in novel disease outbreaks or early technology adoption phases.
- No control group, so causal inference about treatment effects is not possible; results remain descriptive.
- Adaptation rules must be fully pre-specified; post-hoc modifications undermine scientific validity and may introduce bias.
- Subject to selection bias if enrollment is not consecutive or if criteria shift between adaptations.
- Findings have limited external validity beyond the enrolled patient population and setting.
- Regulatory acceptance of adaptive modifications varies by jurisdiction and study context.
Frequently asked
How is an adaptive case series different from a standard case series?
A standard case series collects data under a fixed protocol until a predetermined number of cases is reached or the study period ends. An adaptive case series adds pre-specified rules that allow the sample size, scope, or data collection instruments to be modified based on interim findings. Both designs are observational and descriptive; the adaptive version is distinguished solely by its structured, pre-planned flexibility.
Do I need a data monitoring committee for an adaptive case series?
For studies where adaptation decisions carry patient safety implications — such as early surveillance of a new device — independent interim review by a data monitoring committee is strongly recommended to ensure that adaptation decisions are made objectively. For lower-stakes descriptive series, a less formal review process may be acceptable, but all interim reviews should still be conducted by individuals blinded to the full accumulating data where feasible.
Can I use statistical testing in an adaptive case series?
Adaptive case series are primarily descriptive, and formal hypothesis testing is not the central analytic goal. However, pre-specified interim analyses may use descriptive thresholds (e.g., proportion of adverse events exceeding a defined rate) or simple frequentist stopping rules to guide adaptation decisions. Complex adaptive statistical frameworks designed for randomized trials should not be applied without careful methodological justification.
Is this design accepted by regulatory agencies?
Regulatory acceptance depends on context. The FDA and EMA have issued guidance on adaptive designs primarily for randomized controlled trials. For observational case series, adaptive modifications are viewed more favorably when they are fully pre-specified in a registered protocol, documented transparently, and limited in scope. Consulting regulatory guidance and, where applicable, engaging with the relevant agency early in protocol development is advisable.
What is the minimum number of cases needed before the first interim review?
There is no universal minimum, but the interim review should occur only when sufficient cases have accumulated to make the adaptation decision meaningful — typically at least 20 to 30 cases, depending on the outcome frequency. Reviewing too early (e.g., after 5 cases) risks triggering adaptations based on chance fluctuations rather than genuine signals.
Sources
- Chow, S.-C., & Chang, M. (2008). Adaptive Design Methods in Clinical Trials. Chapman & Hall/CRC. ISBN: 978-1584887775
- Case series. Wikipedia. link ↗
How to cite this page
ScholarGate. (2026, June 3). Adaptive Case Series Study. ScholarGate. https://scholargate.app/en/epidemiology/adaptive-case-series
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Adaptive Cohort StudyEpidemiology↔ compare
- Adaptive Diagnostic Accuracy StudyEpidemiology↔ compare
- Adaptive Randomized Clinical TrialEpidemiology↔ compare
- Case seriesEpidemiology↔ compare
- Prospective Case SeriesEpidemiology↔ compare